PharmaShots | Incisive News in 3 Shots

Subscribe Now

Risk-Benefit Profile

The US FDA Rejects Mallinckrodt's Terlipressin Due to Doubts in its Risk-Benefit Profile

September 15, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us